Search results for Zagotenemab

Zagotenemab, Abbexa, abx831569

Zagotenemab is a monoclonal antibody biosimilar expressed in CHO cells, targeting MAPT, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Zagotenemab is targeting TAU protein, and it has launched a phase II clinical trial in April 2018.

Zagotenemab ELISA Kit, ProteoGenix, KPTX169

Description of Zagotenemab ELISA Kit Introduction Zagotenemab is a novel monoclonal antibody that has recently gained attention as a potential therapeutic target for various diseases. It has been shown to have a high affinity and specificity for its target, making it a promising candidate for drug development. In this article, we will delve into the structure, activity, and potential applications of Zagotenemab, with a focus on its use in enzyme-linked immunosorbent assay (ELISA) kits. Structure of Zagotenemab Zagotenemab is a monoclonal antibody, meaning it is derived from a single clone of immune cells. It is a fully humanized antibody, which means it is composed of human amino acid sequences, making it less likely to cause an immune response in patients. The antibody has a Y-shaped structure, with two identical heavy chains and two identical light chains. Each chain contains a variable region that is responsible for binding to its target, and a constant region that is responsible for the effector functions of the antibody. Activity of Zagotenemab Zagotenemab binds to a specific target protein, known as the therapeutic target, with high affinity and specificity. This target protein plays a crucial role in the development and progression of various diseases, making it an attractive target for drug development. By binding to the target protein, Zagotenemab can block its activity and prevent its harmful effects. Additionally, the binding of Zagotenemab to the target protein can also trigger the immune system to attack and eliminate the target, further enhancing its therapeutic effect. Application of Zagotenemab ELISA Kit ELISA kits are widely used in research and clinical settings to detect and quantify specific proteins or antibodies in biological samples. Zagotenemab ELISA kit utilizes the high affinity and specificity of Zagotenemab to detect and measure the levels of its target protein in various samples. This kit is a valuable tool for researchers studying the role of the target protein in disease development and progression. It can also be used in clinical settings to diagnose and monitor diseases that are associated with the target protein. Advantages of Zagotenemab ELISA Kit One of the main advantages of using Zagotenemab ELISA kit is its high sensitivity and specificity. The kit has been optimized to detect even low levels of the target protein in biological samples, making it a valuable tool for researchers and clinicians. Additionally, the use of fully humanized Zagotenemab in the kit reduces the risk of false results due to immune reactions. Procedure of Zagotenemab ELISA Kit The procedure of using Zagotenemab ELISA kit is similar to other ELISA kits. It involves coating a microplate with the target protein, blocking non-specific binding sites, and then adding the sample and the Zagotenemab antibody. The bound antibody is then detected using a secondary antibody that is conjugated with an enzyme. The enzyme reacts with a substrate to produce a color change, which can be measured using a spectrophotometer. The intensity of the color is directly proportional to the amount of target protein present in the sample. Conclusion In conclusion, Zagotenemab is a promising therapeutic target that has shown potential in various diseases. Its use in ELISA kits provides a valuable tool for researchers and clinicians to study and monitor the levels of the target protein in biological samples. The high sensitivity and specificity of Zagotenemab ELISA kit make it a reliable and efficient tool for detecting and quantifying the target protein. Further research and development of this antibody may lead to the development of novel treatments for diseases associated with the target protein.

Zagotenemab ELISA Kit, Abbexa, abx395058

Zagotenemab ELISA Kit is a quantitative ELISA kit for detection of Zagotenemab.Zagotenemab is a humanized anti-tau antibody derived from MCI-1, Peter Davies' mouse monoclonal antibody against an early pathological conformation of tau. Zagotenemab binds and neutralizes soluble tau aggregates.Preclinical studies in tau transgenic mice showed that immunotherapy with MCI-1 reduced levels of hyperphosphorylated insoluble tau levels and neurofibrillary pathology (Chai et al., 2011).At the 2017 AAIC meeting, Lilly presented data from surface plasmon resonance binding and ELISA assays to assess LY3303560's selectivity to aggregates over monomer and characterize its epitope. LY3303560 reportedly had high affinity to soluble tau aggregate in vitro, at a KD of below 220 picomolar, compared to monomer, KD of 235 nanomolar. The antibody reportedly recognizes a conformational epitope whose primary epitope is in tau's N-terminal region. Intravenous administration to monkeys indicated clearance of 0.15 ml/h/kg and a half-life of 13 days. SC administration indicated a bioavailability of 79 percent, and rat CSF concentration was 0.1 percent of plasma at 24 hours after IV administration (Alam et al., 2017).

Zagotenemab Biosimilar - Research Grade, ichor.bio, ICH5126

Detects human MAPT

Research Grade Zagotenemab (HY086026), abinScience, HY086026